Show simple item record

dc.contributor.authorPerner, Anders
dc.contributor.authorHaase, Nicolai
dc.contributor.authorWinkel, Per
dc.contributor.authorGuttormsen, Anne B
dc.contributor.authorTenhunen, Jyrki
dc.contributor.authorKlemenzson, Gudmundur
dc.contributor.authorMüller, Rasmus G
dc.contributor.authorAneman, Anders
dc.contributor.authorWetterslev, Jørn
dc.date.accessioned2014-09-22T16:53:27Zen
dc.date.available2014-09-22T16:53:27Zen
dc.date.issued2014-07en
dc.date.submitted2014en
dc.identifier.citationIntensive Care Med. 2014, 40 (7):927-34en
dc.identifier.issn1432-1238en
dc.identifier.pmid24807084en
dc.identifier.doi10.1007/s00134-014-3311-yen
dc.identifier.urihttp://hdl.handle.net/2336/326389en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractWe assessed long-term mortality and hospitalisation in patients with severe sepsis resuscitated with hydroxyethyl starch (HES) or Ringer's acetate.
dc.description.abstractThis was an investigator-initiated, parallel-grouped, blinded randomised trial using computer-generated allocation sequence and centralised allocation data that included 804 patients with severe sepsis needing fluid resuscitation in 26 general intensive care units (ICUs) in Scandinavia. Patients were allocated to fluid resuscitation using either 6% HES 130/0.42 or Ringer's acetate during ICU admission. We assessed mortality rates at 6 months, 1 year and at the time of longest follow-up and days alive and out of hospital at 1 year.
dc.description.abstractThe vital status of all patients was obtained at a median of 22 (range 13-36) months after randomisation. Mortality rates in the HES versus Ringer's groups at 6 months were 53.3 (212/398 patients) versus 47.5% (190/400) [relative risk 1.12; 95% confidence interval (CI) 0.98-1.29; P = 0.10], respectively; at 1 year, 56.0 (223/398) versus 51.5% (206/400) (1.09; 95% CI 0.96-1.24; P = 0.20), respectively; at the time of longest follow-up, 59.8 (238/398) versus 56.3% (225/400) (1.06; 95% CI 0.94-1.20; P = 0.31), respectively. Percentage of days alive and out of hospital at 1 year in the HES versus Ringer's groups was 24 (0-87 days) versus 63% (0-90) (P = 0.07).
dc.description.abstractThe long-term mortality rates did not differ in patients with severe sepsis assigned to HES 130/0.42 versus Ringer's acetate, but we could not reject a 24% relative increased or a 4% relative decreased mortality at 1 year with HES at the 95% confidence level.
dc.description.sponsorshipDepartment of Intensive Care, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark b Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, 2100 Copenhagen, Denmark c Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway d Department of Clinical Medicine 1, University of Bergen, Bergen, Norway e Critical Care Medicine Research Group, Department of Intensive Care Medicine, Tampere University Hospital, Tampere, Finland f Department of Surgical Sciences/Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden g Department of Anaesthesia and Intensive Care, Landspitali, Reykjavik, Iceland h Department of Intensive Care, Liverpool Hospital, Sydney, NSW, Australiaen
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://dx.doi.org/10.1007/s00134-014-3311-yen
dc.relation.urlhttp://download.springer.com/static/pdf/136/art%253A10.1007%252Fs00134-014-3311-y.pdf?auth66=1411576467_8651d0835e4f483f5789e2e72ba85983&ext=.pdfen
dc.rightsArchived with thanks to Intensive care medicineen
dc.subject.meshSepsis/mortality*en
dc.subject.meshHydroxyethyl Starch Derivatives/therapeutic use*en
dc.subject.meshIsotonic Solutions/therapeutic use*en
dc.subject.meshResuscitation/methodsen
dc.subject.meshCritical Illnessen
dc.subject.meshPatient Outcome Assessmenten
dc.subject.meshAgeden
dc.subject.meshDouble-Blind Methoden
dc.subject.meshFemaleen
dc.subject.meshFluid Therapy/methods*en
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHospitalizationen
dc.subject.meshHumansen
dc.subject.meshIntensive Care Unitsen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPatient Readmission/statistics & numerical dataen
dc.subject.meshScandinavian and Nordic Countries/epidemiologyen
dc.subject.meshSepsis/therapy*en
dc.subject.meshSeverity of Illness Indexen
dc.titleLong-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate.en
dc.typeArticleen
dc.contributor.departmentDepartment of Intensive Care, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark b Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, 2100 Copenhagen, Denmark c Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway d Department of Clinical Medicine 1, University of Bergen, Bergen, Norway e Critical Care Medicine Research Group, Department of Intensive Care Medicine, Tampere University Hospital, Tampere, Finland f Department of Surgical Sciences/Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden g Department of Anaesthesia and Intensive Care, Landspitali, Reykjavik, Iceland h Department of Intensive Care, Liverpool Hospital, Sydney, NSW, Australiaen
dc.identifier.journalIntensive care medicineen
dc.rights.accessNational Consortium - Landsaðganguren
html.description.abstractWe assessed long-term mortality and hospitalisation in patients with severe sepsis resuscitated with hydroxyethyl starch (HES) or Ringer's acetate.
html.description.abstractThis was an investigator-initiated, parallel-grouped, blinded randomised trial using computer-generated allocation sequence and centralised allocation data that included 804 patients with severe sepsis needing fluid resuscitation in 26 general intensive care units (ICUs) in Scandinavia. Patients were allocated to fluid resuscitation using either 6% HES 130/0.42 or Ringer's acetate during ICU admission. We assessed mortality rates at 6 months, 1 year and at the time of longest follow-up and days alive and out of hospital at 1 year.
html.description.abstractThe vital status of all patients was obtained at a median of 22 (range 13-36) months after randomisation. Mortality rates in the HES versus Ringer's groups at 6 months were 53.3 (212/398 patients) versus 47.5% (190/400) [relative risk 1.12; 95% confidence interval (CI) 0.98-1.29; P = 0.10], respectively; at 1 year, 56.0 (223/398) versus 51.5% (206/400) (1.09; 95% CI 0.96-1.24; P = 0.20), respectively; at the time of longest follow-up, 59.8 (238/398) versus 56.3% (225/400) (1.06; 95% CI 0.94-1.20; P = 0.31), respectively. Percentage of days alive and out of hospital at 1 year in the HES versus Ringer's groups was 24 (0-87 days) versus 63% (0-90) (P = 0.07).
html.description.abstractThe long-term mortality rates did not differ in patients with severe sepsis assigned to HES 130/0.42 versus Ringer's acetate, but we could not reject a 24% relative increased or a 4% relative decreased mortality at 1 year with HES at the 95% confidence level.


This item appears in the following Collection(s)

Show simple item record